NeoLight’s Icon Go With Fluorescein Angiography Capabilities Cleared by FDA for Portable Retinal Imaging

NeoLight announced FDA Class II clearance for its Icon Go portable ophthalmic retinal imaging system with expanded fluorescein angiography (FA) capabilities.

The Icon Go retinal diagnostics device is designed to provide retinal imaging across diverse patient care environments such as the pediatric and neonatal intensive care units, operating room, and emergency rooms. The addition of FA capabilities is particularly important in the diagnosis and management of retinoblastoma patients.

The Icon Go is designed to for the continuum of care of screening and treating newborns. The device employs NeoLight’s Direct Illumination technology for high-resolution and high-contrast retinal imaging, which NeoLight says is particularly beneficial for darkly pigmented fundi. It minimizes scatter at the edge of the field of view. 

The Icon Go with FA will be commercially available in the fourth quarter of 2023.